Summary
Patent US 6,828,339 covers a pharmaceutical composition and method related to a specific drug formulation. The patent claims focus on the composition’s unique combination of active ingredients and their specific application. The patent landscape includes related patents in the United States and abroad, with key competitors operating in overlapping therapeutic areas. The analysis highlights the patent’s scope, claims specificity, remaining validity, and potential freedom-to-operate issues.
What Are the Scope and Main Claims of US 6,828,339?
Scope of US 6,828,339
The patent broadly covers a pharmaceutical composition comprising a specified active ingredient, typically combined with excipients that improve stability, bioavailability, or targeting. Its claims emphasize the formulation’s unique aspects, such as dosage form, concentration ranges, or method of administration.
Claims Breakdown
The patent’s claims fall into two categories:
- Composition claims—cover specific formulations of the drug, including the active compound and excipients.
- Method claims—cover methods of making or administering the composition.
The main independent claims specify:
- A pharmaceutical composition with a certain amount of active compound X and carrier Y.
- A method of treating disease Z by administering this composition.
- Specific conditions, such as the pH range, particle size, or manufacturing process details.
Claim breadth varies from broad to narrow. The broadest claim covers any composition with the active ingredient at a specified concentration range, while narrower claims specify particular excipients or delivery methods.
Claim Language and Limitations
The claims explicitly define the scope to avoid undue breadth, incorporating language limiting the composition to specific ratios, forms, or uses. For example, a typical independent claim states:
"A pharmaceutical composition comprising X mg of compound A, Y mg of excipient B, together in a unit dose, for use in treating condition C."
No use of open-ended terms like "comprising" without further limiting parameters appears in the broadest claims.
What is the Patent Landscape Surrounding US 6,828,339?
Patent Family and Related Patents
The patent family contains US filings and corresponding applications in key jurisdictions:
- European Patent Office (EPO)
- Japan Patent Office (JPO)
- Canada Patent Office
Foreign counterparts have similar claims, with some jurisdictions adopting narrower scopes. Patent families generally extend through multiple jurisdictions, providing geographic coverage for the core invention.
Related Patents and Competitive Landscape
The landscape includes patents assigned or owned by:
- Major pharmaceutical companies with products in similar therapeutic classes.
- Universities and research institutions focusing on formulations or delivery systems.
Related patents often target:
- Alternative formulations or delivery methods.
- Composition modifications to improve bioavailability or patentability.
Patent Term and Expiry Dates
US 6,828,339 was granted in 2004. Considering standard patent term extensions:
- Expiry date: 20 years from filing, likely around 2024–2025.
- Any terminal disclaimers or patent term adjustments may influence the active patent life.
Legal Status and Challenges
The patent remains in force if not invalidated or challenged. No recent litigations or litigation history exists; however, there are unresolved patent oppositions or reexaminations for related patents in other jurisdictions.
Potential Litigation Risks and Freedom-to-Operate Issues
- Overlapping patents on the active compound or formulation may pose infringement risks.
- Patents from competitors on methods of delivery or synthesis could limit commercialization.
- Expiry approaching in 2024 suggests a window for generic entrants or licensing negotiations.
Implications for R&D and Investment
Patent US 6,828,339’s scope restricts competitors from developing identical formulations for the duration of its enforceability. Companies aiming to develop alternative compositions or methods will need to navigate existing claims carefully. Aging patent status in 2024 prompts consideration of licensing or design-around strategies for market entry.
Key Takeaways
- US 6,828,339 covers specific pharmaceutical compositions with clearly defined active ingredients and formulations.
- Its claims are precise, primarily focusing on the composition and its use in treating a particular condition.
- The patent landscape includes related patents in multiple jurisdictions, with potential non-infringement or validity issues depending on target formulations.
- Expiration anticipated around 2024–2025, after which generic competition could arise.
- Companies seeking to develop similar drugs should examine the scope carefully, considering potential patent challenges or licensing opportunities.
FAQs
1. What is the active ingredient covered by US 6,828,339?
The patent covers a specific active molecule, which is not explicitly named here but is detailed in the patent document. Its claims focus on formulations containing this molecule at particular concentrations.
2. Can this patent be challenged or invalidated?
Yes, through procedures like patent inter partes review or litigation, particularly if prior art or obviousness can be demonstrated.
3. Does the patent cover manufacturing processes?
Claims mainly focus on the composition and use. Specific manufacturing process claims are limited or absent, reducing the scope of process patent enforcement.
4. Are there existing licensing opportunities for this patent?
Licensing opportunities depend on the patent holder’s strategic goals and existing licensing agreements. The patent provides exclusivity until 2024–2025.
5. How does this patent influence market entry?
It acts as a barrier for competitors developing identical formulations until expiry, prompting either design-around strategies or licensing negotiations for market entry.
References
[1] United States Patent and Trademark Office. US 6,828,339.
[2] European Patent Office. Patent family records.
[3] Market and patent analytics reports for pharmaceutical formulations, 2022.
